Regulatory
MEDIUMTrigger: Not explained on call.
Monitor: regulatory
Senores Pharmaceuticals Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +18.4%Average5w StreakRe-Entry
In , Senores Pharmaceuticals Ltd (Pharma - API) is outperforming Nifty 500 with +18.4% relative strength. Fundamentals: Average. On a 5-week streak.
Senores Pharmaceuticals Ltd Key Facts
- PE Ratio
- 40.8x
- Market Cap
- ₹4,141 Cr
- PAT Growth YoY
- +113%
- Revenue Growth YoY
- +70%
- OPM
- 31.0%
- RS vs Nifty 500
- +18.4%
Strong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
💪Debt reduced 23% YoY — balance sheet strengthening
🌐FII stake increased 0.6% this quarter
🏛️DII reducing — stake down 1.0%
💰Trading 23% above estimated fair value — significant premium
Key Risks
1. Regulatory
MEDIUM2. Logistics
MEDIUM3. Fx
LOWKey Numbers
PAT Growth YoY
+113%
Stable
Revenue YoY
+70%
Stable
Operating Margin
31.0%
+600 bps YoY
PE Ratio
40.8
Current Price
₹899
Fundamental Score
43/100
Average
3Y PAT CAGR
+80%
Market Cap
4.4K Cr
Valuation
Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
What Are the Key Risks for Senores Pharmaceuticals Ltd?
Earnings deceleration risks from management commentary
Logistics
MEDIUMTrigger: Not explained on call.
Monitor: logistics
Fx
LOWTrigger: Not explained on call.
Monitor: fx
What Is Senores Pharmaceuticals Ltd's Management Saying?
Key quotes from recent conference calls
“The Companies’ current portfolio includes 46 ANDAs and 137 strengths along with a pipeline of 22 ANDAs and 52 strengths. [Risk (regulatory): MEDIUM]”
“month over month in terms of what is the utilization levels, how swiftly we are able to transition our products from US to India [Risk (logistics): MEDIUM]”
“The Corporate Guarantee of upto USD 4,100,000/- (US Dollars Four Million One Hundred Thousand Only) is given by the Company on March 03, 2026 [Risk (fx): LOW]”
How Fast Is Senores Pharmaceuticals Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +70% | +80% | Stable |
| PAT (Net Profit) | +113% | +80% | Stable |
| OPM | 31.0% | +600 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 30, 2026.
Other Top Pharma - API Stocks Beating Nifty 500
Frequently Asked Questions: Senores Pharmaceuticals Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Senores Pharmaceuticals Ltd's latest quarterly results?
Senores Pharmaceuticals Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +112.5% (stable)
- Revenue Growth YoY: +69.9%
- Operating Margin: 31.0% (volatile)
Is Senores Pharmaceuticals Ltd's profit growing or declining?
Senores Pharmaceuticals Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +112.5% (latest quarter)
- PAT Growth QoQ: +13.3% (sequential)
- 3-Year PAT CAGR: +80.0%
- Trend: Stable — consistent growth pattern
What is Senores Pharmaceuticals Ltd's revenue growth trend?
Senores Pharmaceuticals Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +69.9%
- Revenue Growth QoQ: +8.0% (sequential)
- 3-Year Revenue CAGR: +80.0%
How is Senores Pharmaceuticals Ltd's operating margin trending?
Senores Pharmaceuticals Ltd's operating margin is volatile.
- Current OPM: 31.0%
- OPM Change YoY: +6.0% basis points
- OPM Change QoQ: 0.0% basis points
What is Senores Pharmaceuticals Ltd's 3-year profit and revenue CAGR?
Senores Pharmaceuticals Ltd's long-term compounding rates
- 3-Year Profit CAGR: +80.0%
- 3-Year Revenue CAGR: +80.0%
Is Senores Pharmaceuticals Ltd's growth accelerating or decelerating?
Senores Pharmaceuticals Ltd's earnings growth is stable with positive momentum on a sequential basis.
- YoY Acceleration: 0.0% bps
- Sequential Acceleration: -29.6% bps
What is Senores Pharmaceuticals Ltd's trailing twelve month (TTM) performance?
Senores Pharmaceuticals Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹103 Cr
- TTM PAT Growth: +90.7% YoY
- TTM Revenue: ₹589 Cr
- TTM Revenue Growth: +52.6% YoY
- TTM Operating Margin: 26.9%
Is Senores Pharmaceuticals Ltd overvalued or undervalued?
Senores Pharmaceuticals Ltd appears overvalued based on our fair value analysis.
- Valuation Signal: Overvalued
- Current PE: 40.8x
- Price-to-Book: 5.1x
What is Senores Pharmaceuticals Ltd's current PE ratio?
Senores Pharmaceuticals Ltd's current PE ratio is 40.8x.
- Current PE: 40.8x
- Market Cap: 4.1K Cr
How does Senores Pharmaceuticals Ltd's valuation compare to its history?
Senores Pharmaceuticals Ltd's current PE is 40.8x.
- Current PE: 40.8x
- Valuation Assessment: Overvalued
What is Senores Pharmaceuticals Ltd's price-to-book ratio?
Senores Pharmaceuticals Ltd's price-to-book ratio is 5.1x.
- Price-to-Book (P/B): 5.1x
- Book Value per Share: ₹177
- Current Price: ₹899
Is Senores Pharmaceuticals Ltd a fundamentally strong company?
Senores Pharmaceuticals Ltd is rated Average with a fundamental score of 42.73/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +69.9% (10% weight)
- PAT Growth YoY: +112.5% (10% weight)
- PAT Growth QoQ: +13.3% (10% weight)
- Margins stable (10% weight)
Is Senores Pharmaceuticals Ltd debt free?
Senores Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹241 Cr
What is Senores Pharmaceuticals Ltd's return on equity (ROE) and ROCE?
Senores Pharmaceuticals Ltd's return ratios over recent years
- FY2023: ROCE 18.0%
- FY2024: ROCE 12.0%
- FY2025: ROCE 11.0%
Is Senores Pharmaceuticals Ltd's cash flow positive?
Senores Pharmaceuticals Ltd's operating cash flow is negative (FY2025).
- Cash from Operations (CFO): ₹-46 Cr
- Free Cash Flow (FCF): ₹-475 Cr
- CFO/PAT Ratio: -79% (weak cash conversion)
What is Senores Pharmaceuticals Ltd's dividend yield?
Senores Pharmaceuticals Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹899
Who holds Senores Pharmaceuticals Ltd shares — promoters, FII, DII?
Senores Pharmaceuticals Ltd's shareholding pattern (Mar 2026)
- Promoters: 45.8%
- FII (Foreign): 3.6%
- DII (Domestic): 9.6%
- Public: 40.9%
Is promoter holding increasing or decreasing in Senores Pharmaceuticals Ltd?
Senores Pharmaceuticals Ltd's promoter holding has increased recently.
- Current Promoter Holding: 45.8% (Mar 2026)
- Previous Quarter: 45.8% (Dec 2025)
- Change: +0.01% (increasing — positive signal)
How long has Senores Pharmaceuticals Ltd been outperforming Nifty 500?
Senores Pharmaceuticals Ltd has been outperforming Nifty 500 for 5 consecutive weeks, indicating building momentum.
Is Senores Pharmaceuticals Ltd a new momentum entry or an established outperformer?
Senores Pharmaceuticals Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
What are the key risks in Senores Pharmaceuticals Ltd?
Senores Pharmaceuticals Ltd has 3 key risks worth monitoring
- [MEDIUM] Regulatory — Not explained on call.
- [MEDIUM] Logistics — Not explained on call.
- [LOW] Fx — Not explained on call.
What did Senores Pharmaceuticals Ltd's management say in the latest earnings call?
In Q3 FY26, Senores Pharmaceuticals Ltd's management highlighted
- "The Companies’ current portfolio includes 46 ANDAs and 137 strengths along with a pipeline of 22 ANDAs and 52 strengths. [Risk (regulatory): MEDIUM]"
- "month over month in terms of what is the utilization levels, how swiftly we are able to transition our products from US to India [Risk (logistics): M..."
- "The Corporate Guarantee of upto USD 4,100,000/- (US Dollars Four Million One Hundred Thousand Only) is given by the Company on March 03, 2026 [Risk (..."
Is Senores Pharmaceuticals Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Senores Pharmaceuticals Ltd may be worth studying
- Earnings growing at +112.5% YoY
What is the investment thesis for Senores Pharmaceuticals Ltd?
Senores Pharmaceuticals Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +69.9% YoY
Risk Factors (Bear Case)
- Appears overvalued
- Key risk: Regulatory
What is the future outlook for Senores Pharmaceuticals Ltd?
Senores Pharmaceuticals Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: stable
- Margin Trend: volatile
- Valuation: Overvalued
- Key Risk: Regulatory
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.